Adwankar M K, Khandalekar D D, Chitnis M P
Oncology. 1984;41(5):370-3. doi: 10.1159/000225855.
A comparative study of cytostatic combinations was carried out in early and advanced murine leukaemia P388 by using the new protein synthesis inhibitor bouvardin (BVD) along with the known anticancer drugs vincristine (VCR) and cis-diamminedichloroplatinum (DDP). The results indicate that the combination of BVD with DDP enhances the antineoplastic activity in comparison with single-agent therapy in early leukaemia. However, BVD could not indicate its superiority by way of tumour cell killing in three drug combinations, when administered with VCR and/or DDP, against advanced leukaemia.
通过将新型蛋白质合成抑制剂布瓦西丁（BVD）与已知抗癌药物长春新碱（VCR）和顺二氯二氨铂（DDP）联合使用，在早期和晚期小鼠白血病P388中进行了细胞抑制剂组合的比较研究。结果表明，与早期白血病的单药治疗相比，BVD与DDP联合使用可增强抗肿瘤活性。然而，当与VCR和/或DDP联合给药时，BVD在针对晚期白血病的三联药物组合中，未能通过肿瘤细胞杀伤显示出其优势。
